Weijing Tao

Dr. Weijing Tao

The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Physical and Engineering Sciences in Medicine
Verified
Journal Article
Closed access
PDF file
XZXiaoyu Zhou
Xiaoyu Zhou
FGFeng Gao
Feng Gao
SDShaofeng Duan
Shaofeng Duan
LZLianmei Zhang
Lianmei Zhang
YLYan Liu
Yan Liu
WTWeijing Tao
Weijing Tao

23 May 2019 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
WTWeijing Tao
Weijing Tao
HZHui‐Xin Zhang
Hui‐Xin Zhang
LZLian‐Mei Zhang
Lian‐Mei Zhang
FGFeng Gao
Feng Gao
WHWei Huang
Wei Huang
GMGenji Bai MM
Genji Bai MM
Purpose: Ductal carcinoma in situ (DCIS) is a precursor of invasive ductal breast carcinoma (IDC). This study aimed to use pharamcokinetic dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) for the early diagnosis of DCIS.Methods: Forty‐seven patients, including 25 with DCIS (age: 28–70 yr, mean age: 48.7 yr) and 22 with benign disease (age: 25–67 yr, mean age: 43.1 yr) confirmed by pathology, underwent pharamcokinetic DCE‐MRI and IVIM‐DWI in this study. The quantitative parameters Ktrans, Kep, Ve, Vp, and D, f, D* were obtained by processing of DCE‐MRI and IVIM‐DWI images with Omni‐Kinetics and MITK‐Diffusion softwares, respectively. Parameters were analyzed statistically using GraphPad Prism and MedCalc softwares.Results: All low‐grade DCIS lesions demonstrated mass enhancement with clear boundaries, while most middle‐grade and high‐grade DCIS lesions showed non‐mass‐like enhancement (NMLE). DCIS lesions were significantly different from benign lesions in terms of Ktrans, Kep, and D (t = 5.959, P < 0.0001; t = 5.679, P < 0.0001; and t = 5.629, P < 0.0001, respectively). The AUC of Ktrans, Kep, D and the combined indicator of Ktrans, Kep, and D were 0.936, 0.902, 0.860, and 0.976, respectively. There was a significant difference in diagnostic efficacy only between D and the combined indicator (Z = 2.408, P = 0.016).Conclusion: DCE‐MRI and IVIM‐DWI could make for the early diagnosis of DCIS, and reduce the misdiagnosis of DCIS and over‐treatment of benign lesions.

7 April 2026 in Frontiers in Bioinformatics
Verified
Journal Article
Open access
PDF file
XZXiaoyu Zhou
Xiaoyu Zhou
WTWeijing Tao
Weijing Tao
The pharmaceutical research and development (R&D) process is persistently challenged by high financial costs, protracted timelines, and remarkably low success rates. Artificial intelligence (AI) technology, by simulating complex biological systems, has accelerated the innovation of the entire drug discovery pipeline. This review positions AI as a pivotal technology for reengineering the R&D process by utilizing sophisticated molecular representations to predict pharmacodynamic (PD) and toxicological effects significantly earlier. The scope systematically covers the AI foundations in chemoinformatics, detailing how the performance of AI models is intrinsically linked to the quality of molecular representation. We elaborate on representations ranging from robust string-based methods to advanced topological models, including the five key categories of Graph Neural Networks (GNNs), three-dimensional (3D)-aware Geometric Deep Learning (GDL) and emerging Quantum Machine Learning (QML) as well as Hybrid Quantum-Classical Neural Networks (HQNNs). We analyzed the practical application of these models across the drug discovery pipeline, including de novo molecular design with biological foundation models and flow matching generative architectures, data scarcity solutions via Few-Shot Learning and meta-learning, and explainable AI (XAI) for transparent validation. We propose an integrated Q-BioFusion framework that synergizes quantum computing, autonomous experimentation, and generative models to address systemic R&D constraints. We hope future research will improve the geometric fidelity to achieve more accurate and faster 3D molecular prediction and generation, enhance data efficiency, and solve the inherent data sparsity problem in biological assays, and advance integrated XAI workflows. These efforts will ensure transparent, reliable and trustworthy guidance during the computer simulation process of drug design.